Medical News
Platelet Activation in Adult HIV-infected Patients on Antire...
BMC Medicine
This meta-analysis provides evidence that the levels of soluble CD62P and CD40L are elevated in HIV-infected...
19 Nov 2020
Treating HIV-associated Cytomegalovirus Retinitis with Oral...
BMC Infect Dis
Our results from the first introduction of valganciclovir for CMVR in LMIC show encouraging effectiveness and...
18 Nov 2020
HIV‐associated Neurocognitive Impairment in Stable People Li...
HIV Medicine
Despite effective ART roll‐out, NCI remained a prevalent condition in this healthy rural Tanzanian population of...
17 Nov 2020
Virological failure and HIV Drug Resistance Among Adults liv...
HIV Med
There were low proportions with VF and significant RAMs in our cohort, reflecting the durability of current second‐...
09 Nov 2020
eCMEs
Key Trials
ADVANCE Trial: 96-week Efficacy and Safety of DTG Combined with FTC and TAF or TDF versus EFV Combined with FTC and TDF
The ADVANCE trial compared the efficacy and safety of a triple-therapy combination of emtricitabine and dolutegravir plus either of two tenofovir...
DISCOVER Study: Efficacy and Safety of F/TAF with F/TDF for the Prevention of HIV Among Cisgender MSM and Transgender Women Who Have Sex with Men
DISCOVER Study is the first active-controlled, phase 3, non-inferiority trial comparing a new regimen for pre-exposure prophylaxis; emtricitabine...
PRADAR Study: Virological Efficacy of Abacavir/Lamivudine + DRV/r vs Abacavir/ Lamivudine + RAL in Treatment -naïve HIV Patients with CD4<200 cells/μL
The present prospective, multicenter, randomized open-label, 2-arm, phase-3 trial compares the 48-week virological efficacy of two drug regimens...
Switching to FTC/TAF from FTC/TDF in Virologically Suppressed Patients receiving a Boosted PI or an Unboosted Third Agent
This is a 48-week subgroup analysis of evaluating the efficacy and safety of FTC/ TAF by the class of coadministered third agent (boosted PI vs...
Our Publications
Antiretroviral-based Prevention Strategies in HIV
Today, antiretroviral therapy (ART) is not only known to keep HIV-infected patients alive but is also being harnessed as a strategy to prevent...
Antiretroviral Therapy – Current Recommendations
Advances in the treatment of HIV infection has resulted in a dramatic shift, from a deadly infectious disease to a chronic manageable condition....
Datasheet: Lopinavir and Ritonavir (40mg/10mg) Oral Pellets
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This datasheet contains the entire...
Fast Facts: Lopinavir and Ritonavir (40 mg/10 mg) Oral Pellets
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This booklet contains information about...
Patient Education
Live Healthier, Live Longer
This publication features commonly asked questions by HIV patients regarding HIV therapy, drug side-effects, Do’s and Don’ts while on HIV treatment....
Living with Hope
This publication features common questions which arise in HIV patients mind regarding HIV, diagnosis, transmission, treatment and drug side effects. ...
Slide Library
HIV - HCV Coinfection
This slide set covers the epidemiology, disease progression and management of HIV-HCV coinfection in the era of directly acting antivirals available...
HIV - Pre-exposure Prophylaxis (PrEP): Guidance on PrEP Use
PrEP is the use of an antiretroviral medication by HIV-negative individuals to prevent them from acquiring HIV. These slides give an overview on the...
HIV- Post-exposure Prophylaxis (PEP)
Post-exposure prophylaxis (PEP) is the method of preventing exposures of HIV to blood and body fluids and it is considered to be the most important...
Isoniazid Preventive Therapy in HIV Infection
HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection....
Infographics
Poll
Which is your preferred 3rd drug in a first-line regimen?
Efavirenz 600
Efavirenz 400
Dolutegravir
Total votes: 6
